Clinical trials: Plaque Psoriasis Subjects
Plaque Psoriasis
A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK)…
- Trial name
- NCT04080206
- Testing
- 188-0551 Spray, RLD
- Where
- 8 sites in United States, Georgia and 1 more
- Volunteers
- 55 people
- Sponsor
- Therapeutics, Inc.
Psoriasis
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
- Trial name
- AMAGINE-1 (NCT01708590)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 78 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
This is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of PPC-06 (tepilamide fumarate) extended release in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03421197
- Testing
- PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg
- Where
- 74 sites in United States
- Volunteers
- 426 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Chronic Plaque Psoriasis
Safety and Tolerability of Repeat Courses of IM Alefacept
Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept.
- Trial name
- NCT00794807
- Testing
- Alefacept
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Psoriasis
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Calcipotriene is a vitamin D3 analog that has been used as topical therapy in adult subjects with plaque-type psoriasis since 1993.
- Trial name
- NCT01582932
- Testing
- Calcipotriene 0.005% Foam
- Where
- 36 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayne Pharma International Pty Ltd
Nail Psoriasis, Plaque Psoriasis
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
- Trial name
- NCT02016482
- Testing
- Adalimumab
- Volunteers
- 217 people
- Sponsor
- AbbVie
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Moderate to Severe Plaque Psoriasis With Scalp Involvement
The purpose of this study is to determine if etanercept is effective in the treatment of scalp involvement in moderate to severe plaque psoriasis.
- Trial name
- NCT00791765
- Testing
- Etanercept
- Volunteers
- 124 people
- Sponsor
- Amgen
Chronic Scalp Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- SCALP (NCT02267135)
- Testing
- Secukinumab 300 mg
- Where
- 17 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Genital Psoriasis, Scalp Psoriasis
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- UnlIMMited (NCT05969223)
- Testing
- Risankizumab
- Where
- 38 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie
Psoriasis
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
- Trial name
- NCT03240809
- Testing
- Brodalumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Moderate to Severe Plaque Psoriasis
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.
- Trial name
- NCT01260844
- Testing
- briakinumab
- Volunteers
- 12 people
- Sponsor
- Abbott
Psoriasis
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with…
- Trial name
- NCT01235442
- Testing
- 1=Etanercept, 2=Clobetasol propionate foam
- Volunteers
- 592 people
- Sponsor
- Amgen
Psoriasis
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06077331
- Testing
- HS-10374 tablets 1mg, HS-10374 tablets 5mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hansoh BioMedical R&D Company
Psoriasis
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque…
- Trial name
- PSOR-001 (NCT00604682)
- Testing
- CC10004
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Psoriasis
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
- Trial name
- NCT00954915
- Testing
- teplizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Psoriasis
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to determine the superiority and efficacy of infliximab induction therapy in chinese participants with moderate to severe plaque-type psoriasis (scaly skin rash) compared with placebo (an inactive…
- Trial name
- NCT01177800
- Testing
- Infliximab
- Where
- 7 sites in China
- Volunteers
- 129 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Psoriasis
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy.
- Trial name
- NCT04175613
- Testing
- Apremilast
- Where
- 50 sites in United States, Belgium and 7 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis, Psoriasis
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT02581345
- Testing
- M923, Humira
- Where
- 90 sites in United States, Bulgaria and 7 more
- Volunteers
- 572 people
- Sponsor
- Momenta Pharmaceuticals, Inc.